President Trump last week released a blueprint that identifies immediate actions and further opportunities within federal payment programs to lower drug prices. In releasing the blueprint, officials from the Department of Health and Human Services identified four major goals:
Addressing the increase in list prices of drugs
Maximizing the potential of government programs and private payers to leverage negotiating power
Tackling high out-of-pocket costs
Ensuring the practices of foreign markets are not disadvantaging American innovation
The Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs calls for greater transparency of drug prices, better informing consumers about prescription drugs, promoting the use of generic drugs and experimenting with value-based payment through the Center for Medicare & Medicaid Innovation. CHA is reviewing the blueprint’s policy proposals and anticipates additional rulemaking and subregulatory guidance to be released over the coming weeks. Today, the department released a request for information seeking stakeholder feedback to "to help shape future policy development and agency action." Future member engagement on these important policy issues is likely.
This content is restricted to members.
